Coenzyme Q10-containing composition, coenzyme Q10-containing tablet, method for stabilizing coenzyme Q10, and coenzyme Q10-stabilized composition
By using porous starch and fine-grained silicon dioxide to stabilize coenzyme Q10 in compositions with calcium and magnesium, the method enhances stability and maintains effectiveness, addressing the destabilization issues in existing formulations.
Patent Information
- Application Number
- JP2021044636
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-03-18
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2041-03-18
AI Technical Summary
Existing methods for stabilizing coenzyme Q10 in the presence of calcium and magnesium result in decreased manufacturing efficiency and quality due to separate granulation or microencapsulation, leading to destabilization of coenzyme Q10.
Incorporating porous starch and optionally fine-grained silicon dioxide into a composition containing coenzyme Q10, calcium, and magnesium to stabilize coenzyme Q10 by minimizing contact and reaction with calcium and magnesium.
The method significantly improves the stability of coenzyme Q10, maintaining its effectiveness in the presence of calcium and magnesium, as demonstrated by increased residual rates under thermal stress.
Smart Images

Figure 0007596190000006 
Figure 0007596190000007 
Figure 0007596190000001
Abstract
Description
[Technical field]
[0001] The present invention relates to a coenzyme Q10-containing composition, a coenzyme Q10-containing tablet, a method for stabilizing coenzyme Q10, and a coenzyme Q10-stabilized composition. More specifically, the present invention relates to a coenzyme Q10-containing composition, a coenzyme Q10-containing tablet, a method for stabilizing coenzyme Q10, and a coenzyme Q10-stabilized composition for use in the fields of medicines, health foods, and the like. [Background technology]
[0002] Coenzyme Q10, also called CoQ10, coenzyme Q, ubiquinone, ubidecarenone, etc., is a type of coenzyme present in higher organisms. Coenzyme Q10 not only functions as a coenzyme, but also has the effect of improving the oxygen utilization efficiency of the body and the effect of scavenging free radicals, and is said to be involved in various health functions. The clinical effects of coenzyme Q10 have been reported as improvement of symptoms of cardiovascular diseases such as angina pectoris and myocardial infarction, muscular dystrophy, etc., prevention and treatment of high blood pressure, arteriosclerosis, diabetes, periodontal disease, etc., and prevention of side effects of anticancer drugs and psychotropic drugs. In addition, since coenzyme Q10 improves oxygen utilization efficiency, it is also used as a health food and supplement for fatigue recovery, motor function recovery, and weight loss. Thus, coenzyme Q10 is a useful substance as a highly safe active ingredient because it has high physiological activity and exists in the body.
[0003] On the other hand, calcium is not only a major component of bones and teeth, but also plays a role in cell division, cell differentiation, muscle contraction, nerve function, blood coagulation, etc. Magnesium, as a coenzyme, is involved in general metabolic mechanisms such as nerve function, muscle contraction, hormone secretion, and temperature regulation. In recent years, calcium and magnesium intake has tended to be insufficient due to changes in dietary habits, and people are increasingly supplementing their intake with health foods and supplements.
[0004] In the field of health foods and supplements, foods containing not only coenzyme Q10 but also calcium and magnesium have been commercialized. However, it has been revealed that coenzyme Q10 becomes unstable when mixed with calcium and magnesium as minerals. Therefore, foods containing calcium and magnesium and improving the stability of coenzyme Q10 have been studied. For example, Patent Document 1 discloses tablets containing coenzyme Q10, calcium, and magnesium in the form of granules or microencapsulated products. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] JP 2006-320311 A Summary of the Invention [Problem to be solved by the invention]
[0006] The food described in Patent Document 1 is made by mixing coenzyme Q10, calcium, and magnesium into separate granules or microencapsulated materials to improve the stability of coenzyme Q10, and then mixing them to make tablets, capsules, or granules. In this manufacturing method, coenzyme Q10, calcium, and magnesium cannot be mixed at once, and there is a concern that the manufacturing efficiency and quality will decrease due to the increase in manufacturing steps. Therefore, a simple method for stabilizing coenzyme Q10 even in the presence of calcium and magnesium is desired. An object of the present invention is to provide a composition that improves the destabilization of coenzyme Q10 caused by calcium and magnesium, and a method for stabilizing coenzyme Q10. [Means for solving the problem]
[0007] As a result of intensive research into the above problems, the inventors discovered that the destabilization of coenzyme Q10 caused by calcium and magnesium can be improved by adding porous starch to a composition containing coenzyme Q10, calcium, and magnesium, and thus completed the present invention.
[0008] That is, the present invention provides the following [1] to
[11] . [1] A coenzyme Q10-containing composition, comprising coenzyme Q10, porous starch, and calcium or magnesium. This Coenzyme Q10-containing composition can be made to have improved destabilization of Coenzyme Q10 caused by calcium and magnesium due to the action of porous starch. [2] A coenzyme Q10-containing composition according to [1], characterized in that it contains a microporous substance (excluding the porous starch). According to this feature, by containing a microporous substance (excluding the porous starch) in addition to the porous starch, the destabilization of coenzyme Q10 caused by calcium and magnesium can be further improved. [3] The coenzyme Q10-containing composition according to [2], wherein the microporous material is microporous silicon dioxide. According to this feature, by containing fine silicon dioxide, the destabilization of coenzyme Q10 caused by calcium and magnesium can be further improved. [4] The Coenzyme Q10-containing composition according to any one of [1] to [3], wherein the calcium or magnesium is derived from one or two of dolomite and seashells. According to this feature, by using calcium and magnesium derived from dolomite and shells, a highly safe composition can be provided. [5] A coenzyme Q10-containing tablet, comprising the coenzyme Q10-containing composition according to any one of [1] to [4]. This tablet is able to contain stable coenzyme Q10, calcium, and magnesium through the action of porous starch. [6] A method for stabilizing coenzyme Q10 in a composition containing coenzyme Q10 and calcium or magnesium, comprising: A method for stabilizing coenzyme Q10, comprising adding porous starch to a composition containing coenzyme Q10 and calcium or magnesium. According to this method for stabilizing coenzyme Q10, the stability of coenzyme Q10 in a composition containing coenzyme Q10, calcium, and magnesium can be improved by the action of porous starch. [7] A method for stabilizing coenzyme Q10 according to [6], characterized in that a fine porous substance (excluding the porous starch) is added. According to this method for stabilizing coenzyme Q10, the destabilization of coenzyme Q10 caused by calcium and magnesium can be improved by adding a microporous substance (excluding the above-mentioned porous starch) in addition to porous starch. [8] The method for stabilizing coenzyme Q10 described in [6] or [7], wherein the microporous substance is microporous silicon dioxide. According to this method for stabilizing coenzyme Q10, the destabilization of coenzyme Q10 caused by calcium and magnesium can be improved by adding fine silicon dioxide in addition to porous starch. [9] The method for stabilizing coenzyme Q10 according to any one of [6] to [8], wherein the calcium or magnesium is derived from one or two of dolomite and seashells. According to this method for stabilizing coenzyme Q10, a highly safe composition can be provided by using calcium and magnesium derived from dolomite and shells.
[10] A coenzyme Q10 stabilization composition for stabilizing coenzyme Q10 in a composition containing coenzyme Q10 and calcium or magnesium, comprising: A coenzyme Q10 stabilization composition comprising porous starch. According to this Coenzyme Q10 stabilization composition, the action of the porous starch can improve the stability of Coenzyme Q10 in a composition containing Coenzyme Q10, calcium, and magnesium.
[11] A stabilized composition for coenzyme Q10 according to
[10] , characterized in that it contains a microporous substance (excluding the porous starch). According to this stabilizing composition for coenzyme Q10, by adding a microporous substance (excluding the above-mentioned porous starch) in addition to porous starch, the destabilization of coenzyme Q10 caused by calcium and magnesium can be improved. Effect of the Invention
[0009] According to the present invention, it is possible to provide a composition that improves the destabilization of coenzyme Q10 caused by calcium and magnesium, and a method for stabilizing coenzyme Q10. [Brief description of the drawings]
[0010] [Figure 1] FIG. 2 is a graph showing the residual rate of coenzyme Q10 in the calcium-containing tablet of the present invention. [Diagram 2] FIG. 2 is a graph showing the residual rate of coenzyme Q10 in a calcium- and magnesium-containing tablet of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] The coenzyme Q10-containing composition, the coenzyme Q10-containing tablet, and the method for stabilizing coenzyme Q10 of the present invention are described below. The Coenzyme Q10-containing composition, the Coenzyme Q10-containing tablet, and the method for stabilizing Coenzyme Q10 described in the embodiments are merely exemplified to explain the present invention, and are not intended to be limiting.
[0012] [Composition containing coenzyme Q10] The Coenzyme Q10-containing composition of the present invention is a Coenzyme Q10-containing composition containing Coenzyme Q10, porous starch, calcium, and magnesium. First, each component constituting the coenzyme Q10-containing composition will be described in detail. Note that the content of each component is the content in the coenzyme Q10-containing composition unless otherwise specified.
[0013] (Coenzyme Q10) Coenzyme Q10 has a benzoquinone structure and exhibits physiological activity as a coenzyme. There are no particular limitations on the type of coenzyme Q10, so long as it is acceptable for use in pharmaceuticals, foods, veterinary medicines, feed, and the like. Examples of coenzyme Q10 include oxidized coenzyme Q10 (ubiquinone), reduced coenzyme Q10 (ubiquinol), and coenzyme Q10 derivatives. A specific example of Coenzyme Q10 is the product name "Coenzyme Q10 Powder 50" (manufactured by Mitsubishi Chemical Foods Corporation). Specific examples of coenzyme Q10 derivatives include those in which the water solubility, bioabsorbability, and biostability of coenzyme Q10 have been improved by emulsification or water-solubilization treatment, and phosphate compounds of coenzyme Q10. These coenzyme Q10s may be blended alone or in combination of two or more.
[0014] The content of coenzyme Q10 is not particularly limited, and is, for example, 0.05% by mass or more and 2.0% by mass or less. The lower limit is more preferably 0.1% by mass or more, and even more preferably 0.15% by mass or more. On the other hand, the upper limit is more preferably 1.5% by mass or less, and even more preferably 1.0% by mass or less. By setting the content of coenzyme Q10 within the above range, the physiological effects of coenzyme Q10 can be fully exerted.
[0015] (Porous starch) Porous starch is a starch particle that has numerous micropores formed on the surface of the particle by acting on the starch particle with an enzyme or acid. The origin of the starch particle is not particularly limited, but examples thereof include corn, potato, sweet potato, tapioca, sago, wheat, etc. Among these, corn, tapioca, sago, and wheat are preferred, and corn is more preferred, from the viewpoint of reducing the average particle size. A specific example of the porous starch is trade name "Lonfood OWP" (average particle size 15 μm, manufactured by Nippon Starch Chemical Co., Ltd.).
[0016] The coenzyme Q10-containing composition of the present invention contains porous starch, and can improve the destabilization of coenzyme Q10 caused by calcium and magnesium. The mechanism of stabilizing coenzyme Q10 is considered to be that coenzyme Q10 enters the pores of porous starch, and thus the contact with alkali such as calcium and magnesium is suppressed, or that porous starch suppresses the water activity in the composition, and thus the reaction between coenzyme Q10 and alkali is suppressed.
[0017] The dextrose equivalent of the porous starch used in the present invention is, for example, 2 or less. From the viewpoint of the stabilizing effect against coenzyme Q10, it is preferably 1.5 or less, more preferably 1 or less. The dextrose equivalent is an index showing the degree of starch decomposition, and is expressed as the reducing power of a sample per solid content when glucose is taken as 100. The dextrose equivalent can be measured by the official method, Lane-Eynon method ("Starch Sugar Related Industrial Analysis Method" (edited by Starch Sugar Technology Committee)). The less decomposed the starch, the closer the dextrose equivalent value is to 0.
[0018] The average particle size of the porous starch is not particularly limited, and is, for example, 500 μm or less. From the viewpoint of the stabilizing effect against coenzyme Q10, the upper limit is preferably 200 μm or less, more preferably 100 μm or less, even more preferably 50 μm or less, and even more preferably 25 μm or less. From the viewpoint of easy availability, the lower limit is preferably 1 μm or more. The average particle size of the porous starch can be measured by a laser diffraction device, such as a laser diffraction / scattering type particle size distribution measuring device (Horiba, Ltd.).
[0019] The content of the porous starch is not particularly limited, and is, for example, 5% by mass or more and 99% by mass or less. The lower limit is preferably 10% by mass or more, more preferably 20% by mass or more, even more preferably 40% by mass or more, and even more preferably 60% by mass or more, from the viewpoint of the stabilizing effect on coenzyme Q10. On the other hand, the upper limit is preferably 95% by mass or less, more preferably 90% by mass or less, from the viewpoint of the degree of freedom of the composition of the coenzyme Q10-containing composition. The mass ratio of the porous starch content to the calcium and magnesium content (porous starch content / calcium and magnesium content) is not particularly limited and is, for example, 0.2 or more. The lower limit is preferably 0.5 or more, more preferably 2 or more. On the other hand, the upper limit is preferably 100 or less, more preferably 80 or less, and even more preferably 60 or less. By setting the content of the porous starch within the above range, the stabilizing effect on coenzyme Q10 can be further exerted.
[0020] Furthermore, the mass ratio of the porous starch content to the coenzyme Q10 content (porous starch content / coenzyme Q10 content) is not particularly limited and is, for example, 10 to 5000. From the viewpoint of the stabilizing effect on coenzyme Q10, the lower limit is preferably 50 or more, more preferably 100 or more. From the viewpoint of the blending amount of coenzyme Q10, the upper limit is preferably 1000 or less, more preferably 500 or less.
[0021] (Calcium, Magnesium) Calcium and magnesium are essential minerals for the living body, and are not particularly limited as long as they are acceptable for use in pharmaceuticals, foods, veterinary medicines, feeds, etc. Examples of calcium and magnesium include chemically synthesized calcium and magnesium compounds such as chlorides, carbonates, sulfates, hydroxides, and phosphates, calcium and magnesium derived from natural products, etc. From the viewpoint of safety, calcium and magnesium derived from natural products are preferred. Specific examples of calcium include calcium chloride, calcium carbonate, calcium bicarbonate, calcium sulfate, calcium hydroxide, calcium phosphate, calcium hydrogen phosphate, calcium citrate, calcium lactate, calcium acetate, calcium stearate, calcium gluconate, and calcium pantothenate. Specific examples of calcium derived from natural products include calcium derived from shells such as scallop shells and oyster shells, dolomite, eggshell calcium, coral calcium, sea urchin shell calcium, petrified seaweed calcium, pearl calcium, cow bone calcium, fish bone powder calcium, fish scale calcium, seawater calcium, etc. These calcium derived from natural products may be calcined calcium or uncalcined calcium. Specific examples of magnesium include magnesium chloride, magnesium carbonate, magnesium sulfate, magnesium hydroxide, magnesium phosphate, magnesium oxide, magnesium L-glutamate, and magnesium stearate. Specific examples of magnesium derived from natural products include dolomite, coral magnesium, sea urchin shell magnesium, seaweed magnesium, yeast magnesium, bittern, seawater magnesium, and cereal peel magnesium. These magnesium derived from natural products may be calcined magnesium or uncalcined magnesium. In addition, these calcium and magnesium may be blended alone or in combination of two or more.
[0022] The calcium content (calcium element content) is not particularly limited and is, for example, 1.5% by mass or more and 20% by mass or less. The lower limit is more preferably 2.0% by mass or more, and even more preferably 2.2% by mass or more. On the other hand, the upper limit is more preferably 17% by mass or less, and even more preferably 15% by mass or less. The magnesium content (content of magnesium element) is not particularly limited, and is, for example, 2% by mass or more and 15% by mass or less. The lower limit is more preferably 3% by mass or more, and even more preferably 4% by mass or more. On the other hand, the upper limit is more preferably 10% by mass or less, and even more preferably 9% by mass or less. The calcium and magnesium contents may be determined by analyzing the amounts of components in the composition, tablet, etc., or may be calculated from the amounts of calcium and magnesium sources in the composition, tablet, etc. By setting the calcium and magnesium contents within the above ranges, the stabilizing effect of the porous starch on coenzyme Q10 can be further exerted.
[0023] (fine porous material) The coenzyme Q10-containing composition of the present invention preferably further contains a microporous material. The microporous material is a particle having numerous pores other than porous starch, and is not particularly limited as long as it is acceptable for use in medicine, food, animal medicine, feed, etc., and examples thereof include microporous silicon dioxide, activated carbon, microcrystalline cellulose, etc. In addition, these microporous silicon dioxides may be blended alone or in combination of two or more kinds. The fine silicon dioxide is a fine powder of silicon dioxide, silica gel, or fumed silica, and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary medicines, feed, and the like. Examples of the fine silicon dioxide include fine silicon dioxide produced by a wet method in which sodium silicate is directly decomposed with sulfuric acid, and fine silicon dioxide produced by a gas phase method in which silicon tetrachloride is hydrolyzed at high temperature in an oxyhydrogen flame. Specific examples of fine silicon dioxide include the product name "Silopeg 720" (manufactured by Fuji Silysia Chemical Ltd.; average particle size: 2.9 μm). These fine silicon dioxides may be blended alone or in combination of two or more kinds.
[0024] The average particle size of the microporous material is not particularly limited and is, for example, 50 μm or less. The upper limit is more preferably 20 μm or less, and further preferably 10 μm or less. By setting the average particle size of the microporous material within the above range, the stabilizing effect on coenzyme Q10 can be further exerted. The average particle size of the microporous material can be measured by a laser diffraction device, such as a laser diffraction / scattering type particle size distribution measuring device (Horiba, Ltd.).
[0025] The content of the microporous material is not particularly limited, and is, for example, 0.1% by mass or more and 3.5% by mass or less. The lower limit is more preferably 0.3% by mass or more, and even more preferably 0.4% by mass or more. On the other hand, the upper limit is more preferably 3.0% by mass or less, and even more preferably 2.7% by mass or less.
[0026] In addition, the mass ratio of the content of the microporous material to the content of the porous starch (content of the microporous material / content of the porous starch) is not particularly limited, and is, for example, 0.005 or more.The lower limit value is preferably 0.008 or more, more preferably 0.0012 or more, from the viewpoint of further improving the stabilizing effect on coenzyme Q10.
[0027] The mass ratio of the content of the microporous material to the content of calcium and magnesium is not particularly limited, and is, for example, 0.002 to 3.0. The lower limit is more preferably 0.01 or more, and even more preferably 0.015 or more. On the other hand, the upper limit is more preferably 2.7 or less, and even more preferably 2.6 or less. By setting the content of the microporous material within the above range, the stabilizing effect on coenzyme Q10 can be further exerted.
[0028] (Form of Coenzyme Q10-containing composition) The form of the coenzyme Q10-containing composition is not particularly limited as long as it is acceptable for use in medicines, foods, veterinary medicines, feed, and the like, and examples thereof include tablets such as sugar-coated tablets, buccal tablets, coated tablets, and chewable tablets, pills, powders, soft capsules, hard capsules, granules, suspensions, emulsions, syrups, liquids such as elixirs, troches, processed foods, health foods (nutritional supplements, nutritional functional foods, foods for the sick, foods for specified health uses, foods with functional claims, etc.), supplements, foods for the sick (hospital food, food for sick people, nursing food, etc.), confectionery, oils and fats, dairy products, retort foods, microwave foods, frozen foods, seasonings, dietary supplements, beverages, and nutritional drinks.
[0029] [Tablets containing coenzyme Q10] The coenzyme Q10-containing tablet of the present invention is a tablet containing coenzyme Q10, porous starch, calcium, and magnesium. It is preferable that the tablet further contains a fine porous material, and more preferably contains fine silicon dioxide. First, each component constituting the coenzyme Q10-containing tablet will be described in detail. Note that the content of each component indicates the content of the coenzyme Q10-containing tablet unless otherwise specified. In addition, the coenzyme Q10, porous starch, calcium, magnesium, and microporous material (excluding the porous starch) constituting the coenzyme Q10-containing tablet may be the same as the coenzyme Q10-containing composition of the present invention. In addition, the content of coenzyme Q10, porous starch, calcium, magnesium, and microporous material in the coenzyme Q10-containing tablet may be the same as that in the above [coenzyme Q10-containing composition], as long as the coenzyme Q10-containing composition in the description of (coenzyme Q10), (porous starch), (calcium, magnesium) (microporous material) is replaced with the coenzyme Q10-containing tablet and the description is satisfied.
[0030] (Other Ingredients) The coenzyme Q10-containing tablet of the present invention may contain active ingredients and additives as necessary in addition to coenzyme Q10, porous starch, calcium, magnesium, and microporous material.Specific examples of additives include excipients, binders, disintegrants, lubricants, stabilizers, preservatives, colorants, etc.
[0031] The active ingredient is not particularly limited as long as it exhibits efficacy and effect and is acceptable for use in medicines, foods, veterinary medicines, feeds, and the like. Examples of the active ingredient include medicinal ingredients and functional ingredients used in medicines, quasi-drugs, OTC medicines, Chinese herbal medicines, herbal medicines, cosmetics, cosmetic materials, health foods, supplements, veterinary medicines, feeds, and the like. Specific examples of medicinal ingredients and functional ingredients include, for example, vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, folic acid, biotin, niacin, pantothenic acid, iron, copper, zinc, manganese, selenium, chromium, molybdenum, polyglutamic acid, wisteria tea polyphenols, lipid regulators, antidiabetic agents, appetite suppressants, antihypertensive agents, vasodilators, β-adrenergic receptor blockers, cardiac ion channel agents, arrhythmia treatments, anticoagulants, central nervous system function improvers, sympathomimetics, parasympathomimetics, antimuscarinic agonists, dopaminergic agents, tranquilizers, antidepressants, antiepileptic agents, anti Examples of such ingredients include anxiolytics, hypnotics, stimulants, animal-derived substances, plant-derived substances, lapizin, nobiletin, sulforaphane, ampelopsin, curcumins, resveratrols, geraniol, osajin, isoliquiritigenin, hydroxytyrosol, 25-hydroxycholecalciferol, S-adenosylmethionine, anthocyanin, ascorbic acid 2-glucoside, proteoglycan, N-acetylglucosamine, collagen, bilberry extract, carrot powder, gokahi, licorice, peony root, cinnamon bark, fennel, scutellaria, bifidobacteria, lactic acid bacteria, yeast, and dietary fibers such as polydextrose. These medicinal ingredients and functional ingredients may be formulated alone or in combination of two or more.
[0032] The excipient adjusts the bulk of the uncoated tablet and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary drugs, feed, etc. Examples of the excipient include sugars, phosphates, sulfates, etc. Specific examples of the excipient include crystalline cellulose, lactose, sucrose, mannitol, glucose, starch, calcium phosphate, calcium sulfate, etc. These excipients may be used alone or in combination of two or more. By adding excipients, the bulk of the uncoated tablet can be adjusted, making the tablet easier to swallow.
[0033] The binder enhances the binding strength of the powder components and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary medicines, feed, etc. Examples of the binder include cellulose derivatives, synthetic resins, sugars, polyethers, waxes, etc. Specific examples of binders include carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, polymethacrylic acid, glucose, sucrose, lactose, maltose, dextrin, sorbitol, mannitol, polyethylene glycol, paraffin, gum arabic, gelatin, agar, starch, pullulan, etc. These binders may be used alone or in combination of two or more. By adding a binder, it is possible to impart binding power to the powder components and produce a stable solid preparation.
[0034] The disintegrant disintegrates the tablet and enhances the absorbability of the active ingredient. There is no particular limitation on the disintegrant as long as it is acceptable for use in pharmaceuticals, foods, veterinary drugs, feeds, etc. Examples of the disintegrant include sugars, cellulose derivatives, synthetic resins, alginates, etc. Specific examples of disintegrants include corn starch, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose calcium, crystalline cellulose, croscarmellose sodium, carboxymethyl starch sodium, polyvinylpyrrolidone, sodium alginate, etc. These disintegrants may be used alone or in combination of two or more. The addition of a disintegrant can promote disintegration of the tablet and improve absorbability.
[0035] Lubricants reduce the adhesive force of powder components to increase their fluidity, and are not particularly limited as long as they are acceptable for use in pharmaceuticals, foods, veterinary medicines, feed, etc. Examples of lubricants include phyllosilicate mineral powders, silicon oxides, saturated fatty acids, esters, waxes, hardened vegetable oils, fats, polyethers, etc. Specific examples of lubricants include talc, light anhydrous silicic acid, magnesium stearate, calcium stearate, magnesium carbonate, sodium benzoate, palmitic acid, sodium stearyl fumarate, beeswax, hardened soybean oil, cacao butter, polyethylene glycol, etc. These lubricants may be blended alone or in combination of two or more kinds. The addition of a lubricant can prevent tableting problems such as sticking during tablet production.
[0036] The stabilizer suppresses chemical and physical decomposition of the active ingredient, and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary drugs, feeds, and the like. Examples of the stabilizer include inorganic compounds, organic acids, organic acid salts, and vitamins. Specific examples of the stabilizer include sodium hydrogen sulfite, ascorbic acid, sodium edetate, tocopherol, etc. These stabilizers may be used alone or in combination of two or more kinds. By adding a stabilizer, the inactivation of the active ingredient can be suppressed.
[0037] The preservative is not particularly limited as long as it inhibits the growth of microorganisms and is acceptable for use in pharmaceuticals, foods, veterinary medicines, feeds, and the like. Examples of the preservative include benzoates and paraoxybenzoic acid esters. Specific examples of the preservative include sodium benzoate, propyl paraoxybenzoate, methylparaben, propylparaben, etc. These preservatives may be used alone or in combination of two or more kinds. The addition of a preservative can protect the tablets from microbial contamination.
[0038] The colorant is used to improve the palatability and distinguishability of the tablet, and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary medicines, feed, etc., and examples of the colorant include natural dyes and synthetic dyes. Specific examples of colorants include cochineal, carmine, curcumin, riboflavin, annatto, titanium oxide, yellow ferric oxide, ferric oxide, talc, calcined silica, magnesium carbonate, and synthetic food colorants such as Food Blue No. 1, Food Blue No. 2, Food Yellow No. 4, Food Yellow No. 5, Food Green No. 3, Food Red No. 2, Food Red No. 3, Food Red No. 102, Food Red No. 104, Food Red No. 105, and Food Red No. 106. These colorants may be blended alone or in combination of two or more. By adding a coloring agent, the tablet can be colored, and the preference and distinguishability of the coated solid preparation can be improved.
[0039] Other additives include solubilizing agents, surfactants, emulsifiers, antioxidants, glossing agents, foaming agents, moisture-proofing agents, preservatives, fluidizing agents, sweetening agents, flavoring agents, refreshing agents, flavoring agents, fragrances, aromatics, disintegration aids, etc. Furthermore, these additives may be blended alone or in combination of two or more kinds.
[0040] (Coating component) The coenzyme Q10-containing tablet of the present invention may be sugar-coated or film-coated by methods known to those skilled in the art. The coating components are not particularly limited as long as they are acceptable for use in pharmaceuticals, foods, veterinary drugs, feeds, and the like, and examples thereof include sugars, coating bases, thickeners, plasticizers, sweeteners, flavoring substances, colorants, and light protection agents.
[0041] The saccharide is the main component of the sugar coating, and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary medicines, feed, etc. Examples of the saccharide include monosaccharides, disaccharides, and sugar alcohols. Specific examples of sugars include glucose, sucrose, lactose, sorbitol, mannitol, xylitol, erythritol, maltitol, etc. These sugars may be blended alone or in combination of two or more kinds. The addition of sugars can improve the photostability and ease of administration of tablets.
[0042] The coating base is a base in a composition for coating a plain tablet, and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary drugs, feeds, etc. Examples of the coating base include cellulose derivatives, synthetic resins, polysaccharides, etc. Specific examples of coating bases include hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, methylcellulose, pullulan, zein, shellac, yeastrap, etc. These coating bases may be blended alone or in combination of two or more. The addition of a coating base can improve the efficiency and performance of the coating.
[0043] The thickener imparts solubility in water and viscosity to the composition, and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary medicines, feeds, and the like. Examples of the thickener include polysaccharides, water-soluble acrylic acid polymers, and cellulose derivatives. Specific examples of thickeners include sodium alginate, xanthan gum, guar gum, carboxyvinyl polymer, hydroxypropylmethylcellulose, hydroxypropylcellulose, carrageenan, gellan gum, pectin, gum arabic, roasted bean gum, etc. These thickeners may be used alone or in combination of two or more. The addition of a thickener provides binding strength to the powder components, making it possible to produce a stable solid preparation.
[0044] The plasticizer imparts flexibility and elasticity to the composition, and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary medicines, feeds, and the like. Examples of the plasticizer include polyethers, polyhydric alcohols, esters, organic acids, and vegetable oils. Specific examples of the plasticizer include polyethylene glycol, polypropylene glycol, glycerin, glycerol, polyol, triethyl citrate, acetyl monoglyceride, butylphthalyl butyl glycolate, dibutyl tartrate, propylene glycol, glycerol monostearate, tripropioin, diacetin, citric acid, medium chain fatty acid oil, rapeseed oil, etc. The molecular weight of the polyethylene glycol is, for example, 4000 or more and 20000 or less. Specific examples of the polyethylene glycol include PEG6000, PEG8000, etc. These plasticizers may be blended alone or in combination of two or more. By adding a plasticizer, the flexibility and elasticity of the composition for coating the core tablet can be adjusted, and the coating performance can be improved.
[0045] The sweetener is one that imparts sweetness to the tablet and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary medicines, feed, etc. Examples of the sweetener include natural sweeteners and artificial sweeteners. Specific examples of sweeteners include erythritol, sorbitol, aspartame, acesulfame potassium, stevia, sucralose, glycyrrhizic acid, thaumatin, saccharin, saccharin sodium, etc. These sweeteners may be used alone or in combination of two or more. By adding a sweetener, the tablet can be sweetened to make it easier to take.
[0046] The flavoring substance improves the sensory sensation of the tablet in the oral cavity, and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary medicines, feeds, etc. Examples of the flavoring substance include natural vegetable oils and aldehyde compounds. Specific examples of flavoring substances include spearmint oil, peppermint oil, cinnamon oil, fruit essence, benzaldehyde, neral, decanal, tolylaldehyde, 2-dodenal, aldehyde C-8, aldehyde C-9, aldehyde C-12, 2,6-dimethyloctanal, etc. These flavoring substances may be blended alone or in combination of two or more. The addition of flavouring substances can make the tablet easier to swallow.
[0047] The colorant is used to improve the palatability and distinguishability of the tablet, and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary medicines, feed, etc., and examples of the colorant include natural dyes and synthetic dyes. Specific examples of colorants include cochineal, carmine, curcumin, riboflavin, annatto, titanium oxide, yellow ferric oxide, ferric oxide, talc, calcined silica, magnesium carbonate, and synthetic food colorants such as Food Blue No. 1, Food Blue No. 2, Food Yellow No. 4, Food Yellow No. 5, Food Green No. 3, Food Red No. 2, Food Red No. 3, Food Red No. 102, Food Red No. 104, Food Red No. 105, and Food Red No. 106. These colorants may be blended alone or in combination of two or more. By adding a coloring agent, the tablet can be colored, and the preference and distinguishability of the coated solid preparation can be improved.
[0048] The light protection agent imparts light-blocking properties to the tablet, and is not particularly limited as long as it is acceptable for use in pharmaceuticals, foods, veterinary medicines, feed, etc. Examples of the light protection agent include oxides and tar-based dyes. Specific examples of light protection agents include titanium oxide, yellow ferric oxide, ferric oxide, Food Yellow No. 5, and Food Yellow No. 4. These light protection agents may be used alone or in combination of two or more. By adding a light protection agent, the ingredients contained in the tablet can be protected from light.
[0049] Due to the above characteristics, the coenzyme Q10-containing tablet of the present invention can exhibit the effect of improving the destabilization of coenzyme Q10 caused by calcium and magnesium, due to the action of porous starch.
[0050] [Method of stabilizing coenzyme Q10] The method for stabilizing coenzyme Q10 of the present invention is a method of adding porous starch to a composition containing coenzyme Q10, calcium, and magnesium. Incidentally, the coenzyme Q10, porous starch, calcium, and magnesium constituting the method for stabilizing coenzyme Q10 may be the same as those in the above-mentioned coenzyme Q10-containing composition of the present invention.
[0051] The amount of porous starch added is not particularly limited, and may be any amount that satisfies the description in the (Porous Starch) section above in the [Coenzyme Q10-containing Composition] and [Coenzyme Q10-containing Tablet].
[0052] In the method for stabilizing coenzyme Q10 of the present invention, it is preferable to further add a fine porous substance, and it is more preferable to add fine silicon dioxide.
[0053] Due to the above-mentioned characteristics, the method for stabilizing coenzyme Q10 of the present invention can exert the effect of improving the destabilization of coenzyme Q10 caused by calcium and magnesium through the action of porous starch.
[0054] [Coenzyme Q10 stabilization composition] The coenzyme Q10 stabilizing composition of the present invention is a coenzyme Q10 stabilizing composition for stabilizing coenzyme Q10 in a composition containing coenzyme Q10 and calcium or magnesium, and is characterized in that it contains porous starch. According to this Coenzyme Q10 stabilization composition, the action of the porous starch can improve the stability of Coenzyme Q10 in a composition containing Coenzyme Q10, calcium, and magnesium.
[0055] In addition, the coenzyme Q10 stabilizing composition of the present invention may contain a microporous material. By adding a microporous material in addition to the porous starch, the destabilization of coenzyme Q10 caused by calcium and magnesium can be improved. EXAMPLES
[0056] Although examples of the present invention will be described below, the present invention is not limited to these examples, and various modifications are possible within the technical concept of the present invention.
[0057] (Preparation of test samples) The raw materials shown in Table 1 were mixed in the amounts shown in Tables 2 and 3 in a mixer (see-through mixer S-3, Tsutsui Rikagaku Kikai Co., Ltd.) to obtain a mixture. The mixture was compressed into tablets using a single-shot tableting machine (N-30E, Okada Seiko Co., Ltd.) to obtain tablets with a tableting pressure of 1000 kgf, a tablet diameter of 8 mm, and a tablet weight of 300 mg. Coenzyme Q10 Powder 50 contains 50% by mass of coenzyme Q10. Ronfood OWP (average particle size 15 μm) was used as the porous starch, and Pine Flow (average particle size 150 μm) was used as the porous dextrin.
[0058] [Table 1]
[0059] [Table 2]
[0060] [Table 3]
[0061] (Stability test) In the stability test, the prepared test samples were placed in sealed aluminum bags and treated in a constant temperature bath at 50°C for two weeks. After that, the coenzyme Q10 contained in the test samples was measured using high performance liquid chromatography (Shimadzu Prominence, Shimadzu Corporation). The remaining rate of coenzyme Q10 was calculated as a weight percentage (%) of the content before treatment in the constant temperature bath at 50°C.
[0062] [Table 4]
[0063] [Table 5]
[0064] (result) Table 4 and Figure 1 are graphs showing the residual rates of coenzyme Q10 in the tablets of Examples 1 and 2 and Comparative Examples 1 to 4. These tablets were produced as examples of tablets with a low calcium element content (2.45% by mass). In Comparative Example 1, the residual rate of coenzyme Q10 was 67% after treatment for 2 weeks at 50° C. In Comparative Example 3, in which porous dextrin was used, the residual rate was 69%. On the other hand, in Example 1 in which porous starch was added, the residual rate was significantly increased to 96%. In addition, in Comparative Example 2, in which fine silicon dioxide (silica) was further blended with Comparative Example 1, the residual rate of coenzyme Q10 was improved to 81%, and in Comparative Example 4, in which fine silicon dioxide (silica) was further blended with Comparative Example 3, the residual rate was improved to 81%. On the other hand, in Example 2 in which fine silicon dioxide (silica) was further added to Example 1, the residual rate was not improved compared to Example 1.
[0065] Table 5 and Figure 2 are graphs showing the residual rates of coenzyme Q10 in the tablets of Examples 3 and 4 and Comparative Examples 5 to 8. These tablets were produced as examples of tablets with high calcium and magnesium elemental contents (14.42 mass%). In Comparative Example 5, the residual rate of coenzyme Q10 was 59% after treatment for 2 weeks at 50° C. In Comparative Example 7, in which porous dextrin was used, the residual rate was 62%. On the other hand, in the case of tablets containing porous starch, the residual rate increased significantly to 62% in Example 5, in which Pineflow was added, and 80% in Example 7, in which Lonfood was added. In addition, in Comparative Example 6, in which fine silicon dioxide (silica) was further blended with Comparative Example 5, the residual rate of coenzyme Q10 was improved to 80%, and in Comparative Example 8, in which fine silicon dioxide (silica) was further blended with Comparative Example 7, the residual rate was improved to 80%. On the other hand, in Example 4 in which fine silicon dioxide (silica) was further added to Example 3, the residual rate was improved to 88%.
[0066] From the above results, it was confirmed that the incorporation of porous starch has a stabilizing effect on coenzyme Q10.
[0067] In addition, it was confirmed that when the mass ratio of the porous starch content to the calcium and magnesium content (porous starch content / calcium and magnesium content) is small, the stabilizing effect of coenzyme Q10 can be further improved by further adding fine silicon dioxide, which is a fine porous material. [Industrial Applicability]
[0068] The present invention makes it possible to easily produce a composition containing stable coenzyme Q10, calcium, and magnesium, and therefore makes it possible to provide pharmaceuticals, quasi-drugs, drinkable cosmetics, drinkable cosmetics, health foods (nutritional supplements, nutritional functional foods, foods for the sick, foods for specified health uses, foods with functional claims, etc.), supplements, feed, and the like that utilize the beneficial effects of coenzyme Q10, calcium, and magnesium.
Claims
1. A coenzyme Q10-containing composition comprising coenzyme Q10, porous starch, and calcium or magnesium.
2. 2. The coenzyme Q10-containing composition according to claim 1, characterized in that it contains a microporous material (excluding said porous starch).
3. The coenzyme Q10-containing composition according to claim 2, wherein the microporous material is microporous silicon dioxide.
4. The coenzyme Q10-containing composition according to any one of claims 1 to 3, wherein the calcium or magnesium is derived from one or two of dolomite and seashells.
5. A coenzyme Q10-containing tablet comprising the coenzyme Q10-containing composition according to any one of claims 1 to 4.
6. 1. A method for stabilizing coenzyme Q10 in a composition containing coenzyme Q10 and calcium or magnesium, comprising: A method for stabilizing coenzyme Q10, comprising adding porous starch to a composition containing coenzyme Q10 and calcium or magnesium.
7. The method for stabilizing coenzyme Q10 according to claim 6, characterized in that a microporous substance (excluding the porous starch) is added.
8. The method for stabilizing coenzyme Q10 according to claim 6 or 7, wherein the microporous substance is microporous silicon dioxide.
9. The method for stabilizing coenzyme Q10 according to any one of claims 6 to 8, wherein the calcium or magnesium is derived from one or two of dolomite and seashells.
10. A coenzyme Q10 stabilizing composition for stabilizing coenzyme Q10 in a composition containing coenzyme Q10 and calcium or magnesium, comprising: A composition for stabilizing coenzyme Q10, comprising porous starch.
11. 11. The coenzyme Q10 stabilizing composition according to claim 10, characterized in that it contains a microporous material (excluding said porous starch).
Citation Information
Patent Citations
Method for preparing porous starch with high oil absorption rate through preprocessing starch
CN102533908A
Microcapsule type brightening eye cream
CN105213283A
Microcapsule type anti-wrinkle eye cream
CN105310894A
Ubidecarenone tablet
JP1981145214A
New composition and method for producing the same
JP2005104934A
